NCT03746431
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03746431
Title A Phase 1 Study of [225Ac]-FPI-1434 Injection
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Fusion Pharmaceuticals Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN | AUS

Facility Status City State Zip Country Details
City of Hope Duarte California 91010 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
Masonic Cancer Center, University of Minnesota Minneapolis Minnesota 55455 United States Details
Roswell Park Comprehensive Cancer Center Buffalo New York 14203 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Hospital of the University of Pennsylvania Philadelphia Pennsylvania 19104 United States Details
University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
Royal Adelaide Hospital Adelaide South Australia 5000 Australia Details
Austin Hospital Heidelberg Victoria 3084 Australia Details
Juravinski Cancer Center - Hamilton Health Hamilton Ontario L8V 5C2 Canada Details
Princess Margaret Cancer Centre Toronto Ontario M5G 2C1 Canada Details
Centre Hospitalier De I'Universite de Montreal Montreal Quebec H2X 0C1 Canada Details
Quebec University Hospital- Laval Québec Quebec G1R 2J6 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field